Ascendiant Capital Maintains Buy on Aemetis, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 71.3%

Neg 71.3% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:AMTX) with a Buy and lowers the price target from $22 to $20.